Cambridge-based biotechnology company Cambrio yesterday abandoned its proposed £20m-£22m floatation because of lack of interest from investors. It means that its £10m acquisition of the Welsh drugs company Penn lapses, although it may be renegotiated.
- Financial Times 31/7/96 page
Thank you for reading EG
Want to read more? Enjoy a story a day for FREE for one month.